{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:26:39Z","timestamp":1792517199654,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s43441-025-00891-y","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:34:29Z","timestamp":1763390069000},"page":"519-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nitrosamine Contamination in Pharmaceuticals: A Retrospective Regulatory Analysis of USFDA Recalls and Risk Mitigation Strategies (2018\u20132025)"],"prefix":"10.1007","volume":"60","author":[{"given":"Sravani","family":"Yerram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. P.","family":"Muhammad Nizam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Nanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105640","volume":"150","author":"NL Kruhlak","year":"2024","unstructured":"Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, et al. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: development and application of the carcinogenic potency categorization approach (CPCA). Regul Toxicol Pharmacol. 2024;150:105640.","journal-title":"Regul Toxicol Pharmacol"},{"key":"891_CR2","unstructured":"Federation I. The Role of Excipients in Determining N-Nitrosamine Risks for Drug Products. IPEC Position Paper Brussels, Belgium c a b a b. 2022."},{"key":"891_CR3","unstructured":"USFDA. Recommended Acceptable Intake Limits for Nitrosamine Drug SubstanceRelated Impurities (NDSRIs) Guidance for Industry. 2023."},{"issue":"5","key":"891_CR4","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","volume":"112","author":"J Schlingemann","year":"2023","unstructured":"Schlingemann J, Burns MJ, Ponting DJ, Avila CM, Romero NE, Jaywant MA, et al. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci. 2023;112(5):1287\u2013304.","journal-title":"J Pharm Sci"},{"key":"891_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105704","volume":"154","author":"J Bercu","year":"2024","unstructured":"Bercu J, Dirat O, Dobo K, Jolly R, Kenyon M, Harvey J, et al. N-Nitrosamine drug substance related impurities (NDSRIs)\u2013A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight>200 Da. Regul Toxicol Pharmacol. 2024;154:105704.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"4","key":"891_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12247-024-09857-3","volume":"19","author":"G Aglave","year":"2024","unstructured":"Aglave G, Yerram S, Patnam JD, Ajmal C, Nizam VM, Joga R, et al. Proactive approaches to cGMP compliance: insights and key takeaways from USFDA warning letters to pharmaceutical industries between 2019 and 2024. J Pharm Innov. 2024;19(4):49.","journal-title":"J Pharm Innov"},{"issue":"5","key":"891_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12247-024-09869-z","volume":"19","author":"VPM Nizam","year":"2024","unstructured":"Nizam VPM, Yerram S, Patnam JD, Aglave CS, et al. Ensuring product safety: a comprehensive retrospective study of USFDA drug recalls (2019\u20132023). J Pharmac Innov. 2024;19(5):63.","journal-title":"J Pharmac Innov."},{"key":"891_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116349","volume":"249","author":"S Ghijs","year":"2024","unstructured":"Ghijs S, Wynendaele E, De Spiegeleer B. The continuing challenge of drug recalls: insights from a ten-year FDA data analysis. J Pharm Biomed Anal. 2024;249:116349.","journal-title":"J Pharm Biomed Anal"},{"key":"891_CR9","unstructured":"USFDA. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan) 2023 [cited 2025 April 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan."},{"key":"891_CR10","unstructured":"USFDA. DA Updates and Press Announcements on NDMA in Zantac (ranitidine) 2020 [cited 2025 April 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-zantac-ranitidine."},{"key":"891_CR11","unstructured":"USFDA. FDA Updates and Press Announcements on Nitrosamines in Rifampin and Rifapentine 2021 [cited 2025 April 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine."},{"key":"891_CR12","unstructured":"USFDA. FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix) 2022 [cited 2025 April 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix."},{"issue":"5","key":"891_CR13","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1021\/acsomega.8b00846","volume":"3","author":"PV Solanki","year":"2018","unstructured":"Solanki PV, Uppelli SB, Patil RB, Dhokrat PA, Bembalkar SR, Mathad VT. Facile synthesis of Dabigatran etexilate mesylate, an anticoagulant drug, using a novel synthon, N-hexyl-4-nitrophenyl carbonate. ACS Omega. 2018;3(5):5744\u201353.","journal-title":"ACS Omega"},{"issue":"3","key":"891_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12247-025-10009-4","volume":"20","author":"VPM Nizam","year":"2025","unstructured":"Nizam VPM, Yerram S, Ajmal CS, Raghuvanshi RS, Srivastava S. Unraveling trends in USFDAs CDER-regulated drug shortages (2019\u20132024): causes, patterns, and strategic insights for the future. J Pharm Innov. 2025;20(3):99.","journal-title":"J Pharm Innov"},{"key":"891_CR15","unstructured":"Kindelan K. Thousands of bottles of popular antidepressant recalled: 3 things to know. 2024."},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1016\/j.matpr.2022.11.112","volume":"68","author":"R Reddy Gopireddy","year":"2022","unstructured":"Reddy Gopireddy R, Maruthapillai A, Tamilselvi M. Determination of potential nitrosamines NDMA, NDIPA and N-nitroso Duloxetine in Duloxetine Hydrochloride by LC-MS\/MS using APCI source. Mater Today Proc. 2022;68:A7\u201320.","journal-title":"Mater Today Proc"},{"key":"891_CR17","unstructured":"Robledo A, Ardrey T. FDA recalls more than 233,000 bottles of antidepressant over possible cancerous chemical. USA Today. 2024."},{"key":"891_CR18","unstructured":"Qvents. Nitrosocinacalcet Nitrosamine Impurity Triggers Big Recall From Dr.Reddys, Accord 2024 [cited 2025 April 23]. Available from: https:\/\/qvents.in\/nitrosocinacalcet-nitrosamine-ndsri-impurity-accord-dr-reddys-drl-recall-batches\/."},{"key":"891_CR19","unstructured":"Business response form Nebivolol Tablets 2.5 mg Product Recall- December 6, 2024 Recall# 446 [press release]. 2024."},{"issue":"5","key":"891_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70065","volume":"8","author":"MK Mandapaka","year":"2025","unstructured":"Mandapaka MK, Boddu V. A simple and rapid analytical method to detect and quantify the N-nitroso desmethyl diltiazem impurity by liquid chromatography-tandem mass spectrometry in Diltiazem hydrochloride. Separation Sci Plus. 2025;8(5):e70065.","journal-title":"Separation Sci Plus"},{"key":"891_CR21","unstructured":"Keenan J. Glenmark issues another recall, this time for nearly 1.5M bottles of generic ADHD drug. Fierice Pharma. 2025."},{"issue":"4","key":"891_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12247-025-10061-0","volume":"20","author":"P Konda","year":"2025","unstructured":"Konda P, Yerram S, Nuwaid Khader M, Joga R, Nizam VPM, Girhe M, et al. USFDA warning letters: an analysis of compliance in over-the-counter drug products (2020\u20132024). J Pharmac Innov. 2025;20(4):159.","journal-title":"J Pharmac Innov."},{"key":"891_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2024.105672","volume":"152","author":"RA Jolly","year":"2024","unstructured":"Jolly RA, Cornwell PD, Noteboom J, Sayyed FB, Thapa B, Buckley LA. Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine. Regul Toxicol Pharmacol. 2024;152:105672.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"891_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.38212\/2224-6614.1133","volume":"29","author":"FS Aldawsari","year":"2021","unstructured":"Aldawsari FS, Alshehry YM, Alghamdi TS. N-nitrosodimethylamine (NDMA) contamination of ranitidine products: a review of recent findings. J Food Drug Anal. 2021;29(1):39.","journal-title":"J Food Drug Anal"},{"issue":"5","key":"891_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1208\/s12249-019-1376-1","volume":"20","author":"NA Charoo","year":"2019","unstructured":"Charoo NA, Ali AA, Buha SK, Rahman Z. Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities. AAPS PharmSciTech. 2019;20(5):166.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"891_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/CRD.0000000000000323","volume":"28","author":"EA Shephard","year":"2020","unstructured":"Shephard EA, Nawarskas JJ. Nitrosamine impurities in angiotensin receptor blockers. Cardiol Rev. 2020;28(5):262\u20135.","journal-title":"Cardiol Rev"},{"issue":"12","key":"891_CR27","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1021\/acs.oprd.0c00462","volume":"24","author":"FJ King","year":"2020","unstructured":"King FJ, Searle AD, Urquhart MW. Ranitidine\u2014investigations into the root cause for the presence of N-nitroso-N, N-dimethylamine in ranitidine hydrochloride drug substances and associated drug products. Org Process Res Dev. 2020;24(12):2915\u201326.","journal-title":"Org Process Res Dev"},{"key":"891_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124832","volume":"666","author":"D Shakleya","year":"2024","unstructured":"Shakleya D, Alayoubi A, Brown D, Mokbel A, Abrigo N, Mohammad A, et al. Nitrosamine mitigation: NDMA impurity formation and its inhibition in metformin hydrochloride tablets. Int J Pharm. 2024;666:124832.","journal-title":"Int J Pharm"},{"issue":"4","key":"891_CR29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/cpt.2652","volume":"113","author":"A van Haarst","year":"2023","unstructured":"van Haarst A, Smith S, Garvin C, Benrimoh N, Paglialunga S. Rifampin drug\u2013drug\u2013interaction studies: reflections on the nitrosamine impurities issue. Clin Pharmacol Ther. 2023;113(4):816\u201321.","journal-title":"Clin Pharmacol Ther"},{"key":"891_CR30","unstructured":"Clo\u00ebz S, Frick M. N-nitrosamines and Tuberculosis Medicines Rifampicin and Rifapentine. 2021."},{"key":"891_CR31","unstructured":"Steed J. Varenicline nitrosamine drug substance-related impurity (NDSRI) quantification in a varenicline drug product."},{"issue":"4","key":"891_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102102","volume":"64","author":"Z Khan","year":"2024","unstructured":"Khan Z, Harris JR, Dearden L, Strait M, Treend K, Glesmann H, et al. Trends in varenicline use for tobacco cessation, and their implications. J Am Pharm Assoc. 2024;64(4):102102.","journal-title":"J Am Pharm Assoc"},{"key":"891_CR33","unstructured":"USFDA. Liquid Chromatography-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Varenicline Nitrosamine Drug Substance-Related Impurity (NDSRI) in Varenicline Drug Product and Drug Substance"},{"key":"891_CR34","unstructured":"Nudelman R. Nitroso-Derivatives of ACE Inhibitors. 2023."},{"key":"891_CR35","unstructured":"Park B. Nitrosamine Impurity Detected in Certain Lots of Orphenadrine Citrate ER Tablets. MPR Monthly Prescribing Reference. 2022:NA-NA."},{"issue":"8","key":"891_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1039\/D4AY01710B","volume":"17","author":"AD Yadav","year":"2025","unstructured":"Yadav AD, Alaspure AC, Lodha SR, Prajapat AL, Gore AH. Ultrasensitive LC-MS\/MS quantitation of the N-nitroso-dabigatran etexilate impurity in dabigatran etexilate mesylate using an electrospray ionization technique. Anal Methods. 2025;17(8):1797\u2013803.","journal-title":"Anal Methods"},{"key":"891_CR37","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.14233\/ajchem.2023.30576","volume":"35","author":"CH Raju","year":"2023","unstructured":"Raju CH, Rao BM, Jaishetty N, Chakravarthy V, Basavaiah K, Devi D. Characterization and quantitation of N-Nitroso duloxetine impurity in duloxetine hydrochloride drug substance. Asian J Chem. 2023;35:2789\u201396.","journal-title":"Asian J Chem"},{"issue":"6","key":"891_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.70101","volume":"39","author":"SSSK Boppana","year":"2025","unstructured":"Boppana SSSK, Chagarlamudi KK, Damarapurapu R, Gurram VSS, Manglige VK. High-sensitivity LC-MS\/MS approach for accurate quantification of N-nitroso duloxetine in duloxetine pharmaceutical formulations. Biomed Chromatogr. 2025;39(6):e70101.","journal-title":"Biomed Chromatogr"},{"key":"891_CR39","unstructured":"Nebivolol N-Nitroso Nebivolol Cancer Lawsuit Lawyers [Internet]. 2024 [cited April 23, 2025]. Available from: https:\/\/www.yourlawyer.com\/article\/nebivolol-n-nitroso-nebivolol-cancer-lawsuit-lawyers."},{"key":"891_CR40","unstructured":"USFDA. Control of Nitrosamine Impurities in Human Drugs Guidance for Industry. 2024."},{"key":"891_CR41","unstructured":"Technology AC. N-sorb technology for nitrosamine mitigation AND ENSURING GLOBAL REGULATORY COMPLIANCE. 2024"},{"key":"891_CR42","unstructured":"Kumar M. FDA accepts Aptar\u2019s N-Sorb solution for Emerging Technology Program. 2024."},{"key":"891_CR43","unstructured":"Technologies AC. Targeting Nitrosamine Precursors With Novel Active Material Science Scavenger Technologies 2024 [cited 2025 April, 23]. Available from: https:\/\/www.ondrugdelivery.com\/wp-content\/uploads\/2024\/06\/161_2024_MayJun_Oral_Aptar_CSP.pdf."},{"key":"891_CR44","unstructured":"Baertschi S. Mitigating N-Nitrosamine Risks with Novel Active Material Science Innovations 2024 [Available from: file:\/\/\/C:\/Users\/ysrav\/Downloads\/FDA-2023-N-1585\u20130009_attachment_1.pdf."},{"key":"891_CR45","unstructured":"ICH. 2008. [April 23, 2025]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/Q10%20Guideline.pdf."},{"key":"891_CR46","unstructured":"Rivera E. 2022. [April 23, 2025]. Available from: https:\/\/ispe.org\/pharmaceutical-engineering\/march-april-2022\/supplier-qualification-program-key-raw-materials."},{"issue":"12","key":"891_CR47","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1016\/j.xphs.2023.06.013","volume":"112","author":"D Shakleya","year":"2023","unstructured":"Shakleya D, Asmelash B, Alayoubi A, Abrigo N, Mohammad A, Wang J, et al. Bumetanide as a model NDSRI substrate: N-nitrosobumetanide impurity formation and its inhibition in bumetanide tablets. J Pharm Sci. 2023;112(12):3075\u201387.","journal-title":"J Pharm Sci"},{"key":"891_CR48","unstructured":"USFDA. Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products 2021 [cited 2025 April 23]. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities#2."},{"key":"891_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2025.105835","volume":"161","author":"J Bercu","year":"2025","unstructured":"Bercu J, Trejo-Martin A, Chen C, Schuler M, Cheung J, Cheairs T, et al. HESI GTTC ring trial: concordance between Ames and rodent carcinogenicity outcomes for N-nitrosamines (NAs) with rat and hamster metabolic conditions. Regul Toxicol Pharmacol. 2025;161:105835.","journal-title":"Regul Toxicol Pharmacol"},{"key":"891_CR50","unstructured":"ICH. Final Concept PaperAddendum to ICH M7 on Risk Assessment and Control of N-Nitrosamine Impurities 2025."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00891-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00891-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:49:49Z","timestamp":1772117389000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00891-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00891-y","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}